Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect
venglustat | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
IJMS | Free Full-Text | Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
MOVES-PD Clinical Trial Results - Venglustat - Cure Parkinson's
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library
Cells | Free Full-Text | Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Sanofi halts venglustat clinical programme in kidney disease
VENGLUSTAT - Emerging Insight and Market Forecast - 2030
Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress
SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR, IS SUPPORTED BY PRECLINICAL AND PHASE 1 STUDY
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
venglustat - Drug Hunter
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Progress towards therapies for disease modification in Parkinson's disease - The Lancet Neurology
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study - ScienceDirect
Gaucher Treatment Report
Venglustat | C20H24FN3O2S | CID 60199242 - PubChem
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
PERIDOT – Patient ExpeRIence in fabry Disease On venglustaT | M.A.G.I.C Clinic
